ACCE price target published on 22 Oct 2026, 16:00 CEST.
Rating published on 22 Oct 2026, 12:04 CEST.
Price used: €211 at the close on 23 Oct 2026, 17:30 CEST.
Models: P/E comparison and EV/EBITDA comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
102.7% above
-50.7% to fair value
ACCE score
54
out of 100
P/E
70.0x
forward 34.8x
1-year return
-0.4%
Dividend yield
0.32%
Sartorius Stedim Biotech S.A. in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Sartorius Stedim Biotech makes single-use bioprocessing consumables (bioreactor bags, filters, and sensors) and the lab-scale equipment that biopharma manufacturers use to produce monoclonal antibodies and other biologic drugs. Its moat is the switching cost of being qualified into a customer's validated process, which means revenue recurs for as long as a drug stays in production, and the consumables business carries a 44.9% gross margin and a 20.1% operating margin. Near-term revenue growth has slowed to 2.8%, so the case rests on a recovery in customer bioprocess volumes after a destocking cycle and on the operating leverage that comes with it. At 34.7 times forward earnings against a trailing 69.5, the market is pricing in a steep earnings rebound, and the 7.1% ROE shows how much of that rebound is still ahead. This is worth a deeper look to test whether order intake and consumables volumes are turning up before the multiple has to compress or the earnings ramp has to deliver.